Survival:9.5 months
Toxicity Grade:5
Country:United Kingdom
Hospital:Leeds General Infirmary
Patients: This study involved 409 patients recently diagnosed with malignant pleural mesothelioma. The majority (over 90%) of patients were men. They ranged in age from 46 to 85 years of age.

Treatment: Patients were treated in one of three ways: with active symptom control alone, active symptom control and the chemotherapy drugs mitomycin, vinblastine, cisplatin, or active symptom control and vinorelbine. Active symptom control included treatment with steroids, analgesic (pain relieving) drugs, bronchodialators, and palliative radiotherapy).

Toxicity: One patient receiving vinorelbine died from a treatment-related death, and grade 3 neutropenia was reported in 41% of the patients in this treatment group.

Results: The median overall survival was 9.5 months in patients treated with vinorelbine and active symptom control, 8.5 months in those treated with active symptom control and mitomycin, vinblastine, and cisplatin, and 7.6 months in those treated with active symptom control alone.

Correspondence: Dr. Richard Stephens